1239363-40-6

Basic information

• Product Name: 1-Cyclopropyl-4-iodo-1H-pyrazole
• Synonyms: 1-Cyclopropyl-4-iodo-1H-pyrazole
• CAS NO: 1239363-40-6
• Molecular Formula: C₆H₇IN₂
• Molecular Weight: 234.03765
• EINECS: -0
• Mol File: 1239363-40-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1-Cyclopropyl-4-iodo-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclopropyl-4-iodo-1H-pyrazole(1239363-40-6)
• EPA Substance Registry System: 1-Cyclopropyl-4-iodo-1H-pyrazole(1239363-40-6)

Safety Data

• Hazardous Substances Data: 1239363-40-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Cyclopropyl-4-iodo-1H-pyrazole is used as a chemical intermediate for the preparation of dihydropyridinone MGAT2 inhibitors. These inhibitors are of significant interest in the pharmaceutical industry due to their potential role in modulating cellular processes and targeting specific diseases.
As a chemical intermediate, 1-Cyclopropyl-4-iodo-1H-pyrazole can be further modified and functionalized to synthesize a wide range of compounds with diverse biological activities. Its unique structural features make it a valuable building block for the development of new drugs and therapeutic agents.

Upstream product

• 3469-69-0 4-iodopyrazole 
• 411235-57-9 cyclopropylboronic acid 
• 4333-56-6 cyclopropyl bromide 
• 1151814-36-6 1-cyclopropylpyrazole 

Downstream Products

• 1151802-22-0 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 

Relevant articles and documents

Synthesis of NVS-BPTF-1 and evaluation of its biological activity

BPTF (bromodomain and PHD finger containing transcription factor) is a multidomain protein that plays essential roles in transcriptional regulation, T-cell homeostasis and stem cell pluripotency. As part of the chromatin remodeling complex hNURF (nucleoso

SULFONYLUREA DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Therapeutic agent pcnsl (by machine translation)

The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.

DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

AUTOTAXIN INHIBITORS AND USES THEREOF

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.